Erratum to: Vedolizumab in moderately to severely active ulcerative colitis or Crohn’s disease: a guide to its use
Crossref DOI link: https://doi.org/10.1007/s40267-016-0327-0
Published Online: 2016-07-11
Published Print: 2016-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Lyseng-Williamson, Katherine A.
License valid from 2016-07-11